Tumor sections stained with an antibody against vascular endothelial marker CD34 revealed that treatment with 5 mg/kg of hEBV321, EBV321, and Bevacizumab resulted in a weaker CD34 staining and a lower density of CD34 positive blood vessels as compared to saline treated control (P = 0.0034, P = 0.020, and P = 0.040 vs. control for hEBV321, EBV321, and Bevacizumab, respectively) (Figure 4D, E). Here, CD34 is linked to neoplasm.